Overview

  • Product name

    Anti-Filamin A (phospho S1083) antibody [EPR2308]
    See all Filamin A primary antibodies
  • Description

    Rabbit monoclonal [EPR2308] to Filamin A (phospho S1083)
  • Host species

    Rabbit
  • Specificity

    ab109269 only detects Filamin A phosphorylated at Serine 1083.
  • Tested applications

    Suitable for: WB, Flow Cyt, ICC/IFmore details
    Unsuitable for: IHC-P or IP
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Phospho specific peptide corresponding to residues surrounding Serine 1083 of Human Filamin A.

  • Positive control

    • HeLa cell lysates, treated with epidermal growth factor; HeLa cells.
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab109269 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 281 kDa.
Flow Cyt 1/10 - 1/100.

ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.

 

ICC/IF 1/100 - 1/250.
  • Application notes
    Is unsuitable for IHC-P or IP.
  • Target

    • Function

      Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNA may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking.
    • Tissue specificity

      Ubiquitous.
    • Involvement in disease

      Defects in FLNA are the cause of periventricular nodular heterotopia type 1 (PVNH1) [MIM:300049]; also called nodular heterotopia, bilateral periventricular (NHBP or BPNH). PVNH is a developmental disorder characterized by the presence of periventricular nodules of cerebral gray matter, resulting from a failure of neurons to migrate normally from the lateral ventricular proliferative zone, where they are formed, to the cerebral cortex. PVNH1 is an X-linked dominant form. Heterozygous females have normal intelligence but suffer from seizures and various manifestations outside the central nervous system, especially related to the vascular system. Hemizygous affected males die in the prenatal or perinatal period.
      Defects in FLNA are the cause of periventricular nodular heterotopia type 4 (PVNH4) [MIM:300537]; also known as periventricular heterotopia Ehlers-Danlos variant. PVNH4 is characterized by nodular brain heterotopia, joint hypermobility and development of aortic dilation in early adulthood.
      Defects in FLNA are the cause of otopalatodigital syndrome type 1 (OPD1) [MIM:311300]. OPD1 is an X-linked dominant multiple congenital anomalies disease mainly characterized by a generalized skeletal dysplasia, mild mental retardation, hearing loss, cleft palate, and typical facial anomalies. OPD1 belongs to a group of X-linked skeletal dysplasias known as oto-palato-digital syndrome spectrum disorders that also include OPD2, Melnick-Needles syndrome (MNS), and frontometaphyseal dysplasia (FMD). Remodeling of the cytoskeleton is central to the modulation of cell shape and migration. FLNA is a widely expressed protein that regulates re-organization of the actin cytoskeleton by interacting with integrins, transmembrane receptor complexes and second messengers. Males with OPD1 have cleft palate, malformations of the ossicles causing deafness and milder bone and limb defects than those associated with OPD2. Obligate female carriers of mutations causing both OPD1 and OPD2 have variable (often milder) expression of a similar phenotypic spectrum.
      Defects in FLNA are the cause of otopalatodigital syndrome type 2 (OPD2) [MIM:304120]; also known as cranioorodigital syndrome. OPD2 is a congenital bone disorder that is characterized by abnormally modeled, bowed bones, small or absent first digits and, more variably, cleft palate, posterior fossa brain anomalies, omphalocele and cardiac defects.
      Defects in FLNA are the cause of frontometaphyseal dysplasia (FMD) [MIM:305620]. FMD is a congenital bone disease characterized by supraorbital hyperostosis, deafness and digital anomalies.
      Defects in FLNA are the cause of Melnick-Needles syndrome (MNS) [MIM:309350]. MNS is a severe congenital bone disorder characterized by typical facies (exophthalmos, full cheeks, micrognathia and malalignment of teeth), flaring of the metaphyses of long bones, s-like curvature of bones of legs, irregular constrictions in the ribs, and sclerosis of base of skull.
      Defects in FLNA are the cause of X-linked congenital idiopathic intestinal pseudoobstruction (CIIPX) [MIM:300048]. CIIPX is characterized by a severe abnormality of gastrointestinal motility due to primary qualitative defects of enteric ganglia and nerve fibers. Affected individuals manifest recurrent signs of intestinal obstruction in the absence of any mechanical lesion.
      Defects in FLNA are the cause of FG syndrome type 2 (FGS2) [MIM:300321]. FG syndrome (FGS) is an X-linked disorder characterized by mental retardation, relative macrocephaly, hypotonia and constipation.
      Defects in FLNA are the cause of terminal osseous dysplasia (TOD) [MIM:300244]. A rare X-linked dominant male-lethal disease characterized by skeletal dysplasia of the limbs, pigmentary defects of the skin and recurrent digital fibroma during infancy. A significant phenotypic variability is observed in affected females.
      Defects in FLNA are the cause of cardiac valvular dysplasia X-linked (CVDX) [MIM:314400]. A rare X-linked heart disease characterized by mitral and/or aortic valve regurgitation. The histologic features include fragmentation of collagenous bundles within the valve fibrosa and accumulation of proteoglycans, which produces excessive valve tissue leading to billowing of the valve leaflets.
    • Sequence similarities

      Belongs to the filamin family.
      Contains 1 actin-binding domain.
      Contains 2 CH (calponin-homology) domains.
      Contains 24 filamin repeats.
    • Domain

      Comprised of a NH2-terminal actin-binding domain, 24 internally homologous repeats and two hinge regions. Repeat 24 and the second hinge domain are important for dimer formation.
    • Post-translational
      modifications

      Phosphorylated upon DNA damage, probably by ATM or ATR (By similarity). Phosphorylation extent changes in response to cell activation.
      The N-terminus is blocked.
    • Cellular localization

      Cytoplasm > cell cortex. Cytoplasm > cytoskeleton.
    • Information by UniProt
    • Database links

    • Alternative names

      • ABP 280 antibody
      • ABP-280 antibody
      • Actin-binding protein 280 antibody
      • Alpha filamin antibody
      • Alpha-filamin antibody
      • APBX antibody
      • CSBS antibody
      • CVD1 antibody
      • Endothelial actin binding protein antibody
      • Endothelial actin-binding protein antibody
      • Filamin 1 antibody
      • Filamin A alpha antibody
      • Filamin A antibody
      • Filamin-1 antibody
      • Filamin-A antibody
      • FLN antibody
      • FLN-A antibody
      • FLN1 antibody
      • FLNA antibody
      • FLNA_HUMAN antibody
      • FMD antibody
      • MNS antibody
      • NHBP antibody
      • Non muscle filamin antibody
      • Non-muscle filamin antibody
      • OPD antibody
      • OPD1 antibody
      • OPD2 antibody
      • XLVD antibody
      • XMVD antibody
      see all

    Images

    • All lanes : Anti-Filamin A (phospho S1083) antibody [EPR2308] (ab109269) at 1/1000 dilution

      Lane 1 : HeLa cell lysate, untreated
      Lane 2 : HeLa cell lysate, treated with epidermal growth factor (EGF)

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 281 kDa

    • Immunofluorescent staining of HeLa cells using ab109269 at a dilution of 1/100.

    References

    ab109269 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    Answer

    Thank you for your enquiry. Here are the answers to your questions. 1) The Easylink kits are designed to give low level of free label at the end of the reaction. Therefore, there will be no or very low unbounded fluorophore when the conjugated antibody is used on the sample. However, I would strongly recommend performing proper washing after antibody incubation (at least 5-10 min for 3 times), which will also help eliminate any non-specific binding and high background in the experiment. 2) There are no guidelines for storage after conjugation with the kit. In general, the conjugated antibody can be stored at 4°C for up to 6 months. Please include antimicrobial agents and/or stabilizers (e.g. azide, BSA, glycerol, etc.). Some antibodies can be stored at -20°C for longer storage over a year. However, please bear in mind that the storage temperature and duration is not dependent on the conjugation but on the antibody being used. Therefore, if the primary antibody can be stored at 4°C or -20°C, then the conjugated version can also be stored at that temperature. Please refer to the primary antibody storage instructions. 3) The conjugation kits will work with any of the antibody isotypes (IgM, IgG, IgA, IgD, IgE, IgG2a, IgG2b, etc). The labeling chemistry involves free amines present in lysines and at the N-terminus of the antibody. All antibodies have multiple free amine groups, therefore it will work even with ab102969 (IgM isotype). However, one thing that is not compatible is that ab102969 is of ascites purity, which is not recommended for use with Easylink kits. There is a need to purify the antibody using a purification kit like ab109208 Antibody Serum Purification kit (1 purification) before using an Easylink kit. I hope this is the information you are looking for. If everything is what your customer expect, then just simply choose the desired conjugation from the list of Easylink kits (https://www.abcam.com/index.html?pageconfig=resource&rid=13148). If there is anything else that I can help, please let me know.

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up